LATEST
BLK Global PLC: Preliminary Results for the Year Ended 30 June 2026Scientists Launch Legal Challenge to DEA's Proposed Psychedelic Scheduling, Which Would Criminalize Research Compounds and Jeopardize FDA Breakthrough Therapy for Postpartum DepressionTrauma Nurse Builds Clinical Apps Between ShiftsObama Criticises Israel as His Own Record Comes Under ScrutinyVIORA and BioTeke Strengthen Strategic Partnership to Advance Saliva Pregnancy Testing Across EuropeAI Startup AvalonX Emerges From Stealth With $10 Million in Funding From Ridown CapitalGaza, the October 7 Warnings and the Human Cost of Israel’s Security StrategyWhy Good Strategies Lose Momentum Before the Numbers Show ItTransatlantic Coalition: European and Canadian News and Magazine Publishers Unite to Defend Free and Pluralistic MediaDan Rather, Wavelength, Original Productions and Anchor Entertainment Partner to Make RATHER Documentary Free to Stream on YouTube Beginning Monday, October 26, in Support of Independent Journalism and Free SpeechBLK Global PLC: Preliminary Results for the Year Ended 30 June 2026Scientists Launch Legal Challenge to DEA's Proposed Psychedelic Scheduling, Which Would Criminalize Research Compounds and Jeopardize FDA Breakthrough Therapy for Postpartum DepressionTrauma Nurse Builds Clinical Apps Between ShiftsObama Criticises Israel as His Own Record Comes Under ScrutinyVIORA and BioTeke Strengthen Strategic Partnership to Advance Saliva Pregnancy Testing Across EuropeAI Startup AvalonX Emerges From Stealth With $10 Million in Funding From Ridown CapitalGaza, the October 7 Warnings and the Human Cost of Israel’s Security StrategyWhy Good Strategies Lose Momentum Before the Numbers Show ItTransatlantic Coalition: European and Canadian News and Magazine Publishers Unite to Defend Free and Pluralistic MediaDan Rather, Wavelength, Original Productions and Anchor Entertainment Partner to Make RATHER Documentary Free to Stream on YouTube Beginning Monday, October 26, in Support of Independent Journalism and Free Speech
Business

ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

Richard Powell  1 min read

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that new preclinical data for ProMIS’ lead candidate for AD, PMN310, will be presented as a virtual short oral poster presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2023) to be held on March 28-April 1, 2023 virtually and in Gothenburg, Sweden.

  Presentation Details:

 

Title: Differentiation of PMN310 from Other Amyloid-Beta-Directed Antibodies: Ability to Selectively Target Toxic Brain Oligomers Despite Competing Monomers and Plaque  

The virtual poster (P0214) will be available during the AD/PD 2023 medical conference starting March 28, 2023 and available on ProMIS’ website.

 

ProMIS Neurosciences Inc. is a development stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA. The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.

 

www.promisneurosciences.com

Related articles

Top